

About TTBD

For Inventors

Available Technologies

Startups

NEWS

After launching in the summer of 2012 as a spin-out from the University of Portland and Oregon Health & Science University (OHSU) joint Technology Entrepreneurship Program, Nzumbe Inc. has been rapidly attracting funding from the University of Portland (100K Business Plan Competition), the National Collegiate Inventors & Innovators Alliance, the Oregon Translational Research & Development Institute (OTRADI), and the Portland Development Commission (PDC). Most recently, Nzumbe was awarded a Phase I STTR grant from the NIH to continue the development of a high-throughput epigenetic drug discovery platform in partnership with OHSU and OTRADI. Nzumbe is an Oregon-based biotech that uses its innovative drug discovery platform to help pharmaceutical companies accelerate and develop breakthrough therapies in cancer and other challenging diseases.

EVENTS



Wednesday, November 5, 2014

OHSU's MedTech Alliance Launch Event

5:00 PM - 7:30 PM

CLSB, Oregon Dental Association Lecture Room

REGISTER HERE

Thursday, November 6, 2014

OHSU's Third Annual Startup Symposium

8:30 AM - 6:30 PM

Marquam Hill Campus, OHSU Old Library Auditorium

REGISTER HERE

Tuesday, December 16, 2014

TTBD Lunch & Learn Series: "The Basics of Starting a Company from University"

12:00 PM - 1:00 PM

Marquam Hill Campus, Mackenzie Hall 2201

CONTRAVE WEIGHT LOSS DRUG REACHES FDA APPROVAL

TTBD is pleased to announce that a drug from Orexigen Therapeutics Inc., called Contrave, has been approved by the FDA. This drug helps with weight management, along with a reduced-calorie diet and increased physical activity, in adults with an initial body mass index of 30 kg/m² or greater (obese), or 27 kg/m² or greater (overweight) who also have at least one weight-related comorbid condition.

Contrave has two components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Nonclinical studies suggest that naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the hypothalamus, which regulates appetite, and the dopamine circuit, which serves as a reward system.

Orexigen is an OHSU startup company that was created in 2003. The FDA's approval of Contrave represents a significant milestone for both Orexigen and OHSU. Sales through Orexigen's North American partner, Takeda Pharmaceuticals, are set to begin this fall. For more information, please click [HERE](#) to view the press release.

2014 TECHNOLOGY TRANSFER & BUSINESS DEVELOPMENT AWARDS

On October 6, TTBD hosted the 2014 Technology Transfer & Business Development Awards to recognize OHSU community members for their collaborations and efforts in licensing, sponsored research, patenting, and entrepreneurship in the previous fiscal year. The ceremony drew an enthusiastic crowd to the Portland State University lecture hall at the new Collaborative Life Sciences Building.

We'd like to congratulate all of the researchers who were recognized at this year's TTBD Awards ceremony, including:



**Technology Transfer
Achievement Award**

**Arthur Vandembark,
PhD**
Senior Research Career
Scientist, VAMC



**New Inventor of the
Year Award**

**Michael P. Hutchens,
MD, MA**
Associate Professor,
Anesthesiology &
Perioperative Medicine



**Business Partnership
Achievement Award**

**Sanjiv Kaul,
MD**
Ernest C. Swigert Chair
of Cardiovascular
Medicine

For more information on each award winner, please visit the [Research News Blog post](#) here.

WHAT IS MEDTECH ALLIANCE?

OHSU's MedTech Alliance was founded by TTBD and the Oregon Clinical & Translational Research Institute (OCTRI). This program connects investors and industry collaborators with OHSU inventors and OHSU medical technologies. OHSU has many innovative medical technology inventions in the device and diagnostic spaces. Some of these inventions could benefit from additional resources and support before they can be commercialized. The MedTech Alliance provides a mechanism for potential investors and industry collaborators to identify OHSU medical technologies, including early stage technologies, that have a realistic chance for commercialization. The goal of the MedTech Alliance is to initiate collaborations and advance OHSU technologies.

On Wednesday, November 5, 2014, the MedTech Alliance will hold its first launch event for the program. A series of OHSU inventors will provide brief "snapshot" presentations of their technologies followed by a networking poster session. Technologies highlighted in this event will focus on care-related medical devices including: Cardiovascular disease risk assay (Dave Farrell, PhD, FAHA), Deep brain stimulation for body weight reduction (Kim Burchiel, MD, FACS), Genomic panel for detection of bladder cancer recurrence (Trevor Levin, PhD), Stroke rehabilitation system (Paul Cordo, PhD), and Video diagnosis (Bill Kelly, MBA).

To read more on the MedTech Alliance, please click [HERE](#). To attend the event, a registration link is provided in the Events section of this Newsletter.

TTBD EDUCATION: AGREEMENTS 101

Are you preparing to have a discussion with an industry or academic collaborator where you will be sharing unpublished or proprietary information? Do you get requests from industry partners that include funding part of your research? Perhaps you've returned from a professional conference and you're excited to collaborate with new academic and industry folks who share synergies with your research area. Or maybe you are just trying to stretch your grant funding dollars (to the moon if possible) by receiving "free" samples to support your work, or you need a particular formulation of compound that is only available directly from a pharmaceutical company. If any of these scenarios sound familiar then it is likely that you will need to engage with TTBD for some kind of a contract or agreement.

The Industry and Academic Collaborations Team within the TTBD office is primarily responsible for helping faculty navigate the obligations and complexities of Non-Disclosure Agreements (NDAs), Material Transfer Agreements (MTAs) and any type of industry sponsored agreement related to preclinical research or post clinical retrospective analyses. We will help you figure out what type of agreement is appropriate for your particular situation. Feel free to contact us at mta@ohsu.edu with questions or inquiries.

NEW STAFF MEMBERS



Travis G. Cook, MS, MBA
Senior Technology Development Manager

Travis is a cross-functional international business development professional with experience in managing, negotiating, and closing early-, late-, and commercial-stage definitive agreements. He received a M.S. in chemistry from UC San Diego, and a M.B.A. from Willamette University. Travis is a co-inventor on 7 patent applications and is a co-author of several peer-reviewed publications, including a case study in the management textbook, Building a Case for Biotechnology. Prior to joining TTBD, Travis was the Director of Business Development at Galena Biopharma, Inc. (Nasdaq: GALE) and has held appointments at OHSU, Kalypsys, Inc., Ansata Therapeutics, Inc., and Mixture Sciences, Inc. Travis is currently a Senior Technology Development Manager in TTBD.



Priya Ramu, PhD
Agreements Officer

Priya received her Ph.D. from the Center for Pharmaceutical Biotechnology at the University of Illinois at Chicago, where she studied programmed ribosome stalling which causes antibiotic resistance. Prior to that, she contributed to tuberculosis research in AstraZeneca, India and has a background in pharmaceutical sciences. Priya spent nine months as an intern in TTBD, assisting the OHSU research consortia members and other researchers in engaging with industry and also performing market research on biotech companies. She is now an Agreements officer in TTBD, managing industry sponsored research, materials transfer and other agreements for OHSU.